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Abstract
Background: The expression of metallothionein (MT) is involved in acquiring resistance to immune-mediated
apoptosis; it is also a negative regulator of the immune response. Nasal polyps are typified by a resistance to
immune-mediated apoptosis as well as by excessive immune cell infiltration. RCAS1 (receptor-binding cancer
antigen expressed on SiSo cells) is a membrane protein capable of inducing the apoptosis of CTLs and NK cells.
The aim of the present study has been to explore the expression of metallothionein with respect to immune cell
presence and immune cell activity. In our study, we identified immune cells using CD4 and CD68 antigen
expression and evaluated their activity using CD25 antigen expression. We then analyzed metallothionein, RCAS1,
CD25, CD4, and CD68 in a sampling of 50 nasal polyps using the immunohistochemistry method. We were able to
divide the nasal polyps into three main groups according to their predominant immune cell infiltration:
eosinophilic nasal polyps (21 cases), lymphocytic nasal polyps (17 cases), and neutrophilic nasal polyps (12 cases).
Results: In the present study, statistically significant differences between the MT expression in the epithelium and
that in the stroma of the nasal polyps along with the accompanying alterations in activation markers on immune
cells were found and the number of macrophages in both the eosinophilic and the lymphocytic nasal polyps was
assessed. RCAS1-expressing macrophages were found only in the eosinophilic nasal polyps.
Conclusion: MT expression seems to favor the survival of nasal polyp epithelial cells in the adjacent area of
increasingly cytotoxic immune activity. RCAS1-expressing macrophages seem to participate in creating the immune
suppressive microenvironment and so help to sustain local inflammation.
Background
Chronic rhinosinusitis with nasal polyps is considered a
subdisease of chronic rhinosinusitis [1]. Nasal polyps are
found in 20% of the cases of chronic rhinosinusitis [2],
and most polyps originate in the clefts of the osteomea-
tal complex. The overall prevalence rate for the disease
in the general population ranges from 1-4% [3,4]. The
immune cell infiltration identified in nasal polyps is a
mixed one; it includes eosinophils, and these constitute
more than 10% of the cells of nasal polyps in the Cauca-
sian population. The number of CD3 positive and CD25
positive activated T lymphocytes also increases in nasal
polyps [5]. The pattern of immune cell infiltration to
the polyps in non-allergic as opposed to allergic patients
who have chronic rhinosinusitis with nasal polyps has
been demonstrated to be different. In non-allergic
patients, fewer CD4+ cells in the epithelium and more
CD8+ cells in the lamina propria were found than in
the same tissues of the patients who had allergies. The
number of macrophages increases as well in nasal
polyps. These cells have enhanced mannose receptor
expression, which is capable of phagocytosis and signals
transduction for pro-inflammatory mechanisms [6,7].
The histomorphological characterization of nasal
polyp tissue reveals frequent epithelial damage, a thick-
ened basement membrane, and edematous or sometimes
fibrotic stromal tissue with a reduced number of vessels
and glands [3].
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icant participating factors include infectious as well as
noninfectious inflammation and anatomic and genetic
abnormalities. Allergic and nonallergic rhinitis as well as
allergic fungal sinusitis, aspirin intolerance, asthma, cys-
tic fibrosis, primary ciliary dyskinesia, and Kartagener
syndrome are all associated with nasal polyps. Further-
more, nasal polyps are believed to represent the final
stage of chronic nasal inflammation [1].
As in our previous study, we demonstrated that nasal
polyps develop resistance to immune-mediated apopto-
sis and are able to express factors by which the activity
of infiltrating immune cells can be regulated. In the pre-
sent study we have focused on the analysis of metal-
lothionein in nasal polyps [8].
Metallothionein (MT) is a small (approx. 7 kDa),
thiol-rich protein [9]. The expression and induction of
metallothionein has been associated with protection
against both oxidative stress and apoptosis. This is
because thiols participate in complexing with divalent
metal cations. When metallothionein binds to essential
divalent metals (zinc and copper), it may serve as a
metal reservoir for apo-enzymes and zinc-finger tran-
scription regulators [10]. Apoptosis has also been
increased in MT-null cells [11]. MT has been found to
be associated with the enhanced proliferation of cells in
esophageal, breast, and nasopharyngeal cancers [12-14].
Since MT function includes the maintenance of proper
intracellular Zn
2+ level, and the proper intracellular
Zn
2+ level is responsible for the regulation of caspase-3
activity, Zn
2+ has been observed to inhibit caspase-3
activity. Caspase -3 controls the essential step of apopto-
sis and is responsible for DNA fragmentation [15]. The
potential role of metallothionein in the modulation of
apoptosis may depend on the nuclear/cytoplasmic locali-
zation of MT in the cell. Cytoplasmic MT is thought to
protect against cytotoxicity whereas nuclear MT pro-
tects against genotoxicity [16].
E. Canpolat et al. has proposed that MT may serve as
a negative regulator of thei m m u n er e s p o n s ea n ds o
suppress the autoimmune attack on self-tissues. Indeed,
the induction of MT by glucocorticoids may explain the
role they play in treating autoimmune diseases [17].
The aim of the present study has been to evaluate MT
immunoreactivity in nasal polyps with respect to the
type of immune cell infiltration present. For this pur-
pose, we have considered the presence of macrophages,
CD4 positive Th lymphocytes, and CD25 antigen immu-
noreactivity. We have also repeated the analysis of
RCAS1 expression so that we can consider its expres-
sion in relation to immune cell presence and activity.
The major function of RCAS1 expression is to inhibit
activated immune cells, such as T and B lymphocytes
and NK cells, and to induce their apoptosis. RCAS1 as
expressed on cancer cells is responsible for both tumor
escape from host immunological surveillance and the
creation of immune tolerance toward tumor cells
[17,18]. Moreover, it has been shown that macrophages
stimulated with LPS (lipopolysaccharide)-enhanced
RCAS1 expression together with the induced apoptosis
of the progenitor cells of the erythroblast line through
RCAS1 play an important regulatory role in erythropo-
esis [19,20]. Furthermore, it has been shown that
RCAS1 can be found only on activated monocytes
[19,21]. Because RCAS1-positive macrophages represent
a population of cells capable of regulating immune sys-
tem cell activity in a negative manner, their presence in
the nasal polyp microenvironment may also help to cre-
ate a local immunosuppressive microenvironment.
Results
The analysis of MT expression in nasal polyps
Metallothionein immunoreactivity was identified in all
the examined nasal polyp tissue samples and this immu-
noreactivity was intracellular.
Eosinophilic nasal polyps
MT immunoreactivity was found in all the examined tis-
sue samples derived from the eosinophilic nasal polyps
and was present in the epithelium lining the nasal
polyps; it represented a nuclear pattern of staining
(Table 1). MT immunoreactivity was also present in the
stroma of nasal polyps where it represented a nuclear
and cytoplasmic staining pattern (Table 2).
Figure 1. MT immunoreactivity in the stroma of nasal
polyps.
Lymphocytic nasal polyps
MT immunoreactivity was identified in all the examined
lymphocytic nasal polyps, and as was the case with
the eosinophilic nasal polyps, was found to be present
Table 1 MT immunoreactivity in the epithelium of nasal
polyps.
Variables Number MT immunoreactivity in the
epithelium
-+ 1 + 2 + 3
Eosinophilic nasal polyps 21 0 2 (10%) 19 (90%) 0
Lymphocytic nasal polyps 17 0 4 (24%) 13 (76%) 0
Neutrophilic nasal polyps 12 0 12 (100%) 0 0
Table 2 MT immunoreactivity in the stroma of nasal
polyps.
Variables Number MT immunoreactivity in the
stroma
-+ 1 + 2 + 3
Eosinophilic nasal polyps 21 0 4 (19%) 15 (71%) 2 (10%)
Lymphocytic nasal polyps 17 0 7 (42%) 9 (53%) 1 (5%)
Neutrophilic nasal polyps 12 0 12 (100%) 0 0
Dutsch-Wicherek et al. BMC Immunology 2010, 11:10
http://www.biomedcentral.com/1471-2172/11/10
Page 2 of 9in both the epithelial cells and the stroma (Table 1,
Table 2).
Table 1. MT immunoreactivity in the epithelium of
nasal polyps.
Table 2. MT immunoreactivity in the stroma of nasal
polyps.
Figure 2. MT immunoreactivity in epithelium (hori-
zontal arrows) and stroma (vertical arrows) of nasal
polyps.
Neutrophilic nasal polyps
The MT staining pattern was weak in the epithelium
lining both the polyps and the stroma. No other exam-
ined antigens (such as CD25, CD4, or CD68) were iden-
tified in the neutrophilic nasal polyps. On account of
these findings, the neutrophilic nasal polyps were
excluded from further consideration in the study.
Interestingly, exceptionally high MT expression was
found in the stroma of the nasal polyps that were adja-
cent to bone. Moreover, the osteoblasts of the adjacent
bone showed high levels of MT immunoreactivity. This
immunoreactivity was observed in all the bone frag-
ments obtained for the study with nasal polyps regard-
less of the type of the immune cell infiltration in the
polyps. No other bone fragment regions exhibited MT
immunoreactivity.
Figure 3. MT immunoreactivity in the bone adjacent
to the nasal polyps.
Comparison of MT immunoreactivity in eosinophilic and
lymphocytic nasal polyps
MT expression within the epithelium was statistically
significantly higher in the eosinophilic than in the lym-
phocytic nasal polyps (p = 0.02). MT stromal expression
was higher in the eosinophilic nasal polyps than in the
lymphocytic, but the difference was not statistically sig-
nificant. A statistically significant correlation, however,
was found between MT expression in the epithelium
and in the stroma (r = 0.61, p < 0.0001).
The analysis of immune cells in nasal polyps
CD68 positive cells
CD 68 positive cells (macrophages) were identified in
both the stroma and the epithelium lining the nasal
polyps. The number of scattered cells in the stroma ran-
ged from 0 to 3 in a hpf. In the edematic area of the
nasal polyp stroma, the number of inflammatory cells
was high, and the number of CD68 positive cells
increased to 8-11 in a hpf. Overall, the number of
macrophages was statistically significantly higher in the
tissue of the eosinophilic nasal polyps than in that of
the lymphocytic nasal polyps (p < 0.01) (Table 3).
Table 3. CD68 immunoreactivity in nasal polyps.
Figure 1 MT immunoreactivity in the stroma of nasal polyps
(arrows).
Figure 2 MT immunoreactivity in the epithelium (horizontal
arrows) and stroma (vertical arrows) of nasal polyps.
Figure 3 MT immunoreactivity in the bone adjacent to nasal
polyps (arrows).
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While in our previous study we identified RCAS1
expression in nasal polyps, in the current study we have
also evaluated this expression in nasal polyps [8]. Strong
cytoplasmic RCAS1 immunoreactivity was found in the
epithelium lining the polyps, and was additionally pre-
sent in the extra-cellular mucus. Moreover, RCAS1
immunoreactivity was observed in the mucous glands,
but was weaker than in the surface epithelium. As in
the previous study, the RCAS1 immunoreactivity level
in the epithelium lining the polyps was significantly
higher in the lymphocytic nasal polyps than in the eosi-
nophilic polyps. Likewise, in the present study the level
of RCAS1 immunoreactivity in the epithelium lining the
nasal polyps was significantly higher in the lymphocytic
nasal polyps than in the eosinophilic polyps (p < 0.05)
(Table 4). Additionally the stroma of eosinophilic polyps
contained single RCAS1 positive cells that were dis-
persed within the immunological infiltration and were
identified as CD68 positive cells. These same cells were
not found in the lymphocytic nasal polyps.
Table 4. RCAS1 immunoreactivity in the epithelium of
nasal polyps.
Figure 4. RCAS1 positive macrophages within eosino-
philic nasal polyps.
CD68 RCAS1 positive cells were observed to migrate
from the stroma of the nasal polyps through the epithe-
lium (single cells seen within the epithelium) to the
mucus.
Figure 5. RCAS1 positive macrophages migrating
through epithelium of the nasal polyps to the mucus.
CD4 antigen expression was observed in 47.65% of the
eosinophilic nasal polyps and in 66.7% of the lymphocy-
tic nasal polyps. No differences, however, were observed
between the eosinophilic and lymphocytic nasal polyps
with respect to CD4 expression (Table 5).
Table 5. CD4 antigen immunoreactivity in nasal
polyps.
CD 25 expression was statistically significantly higher
in the eosinophilic nasal polyps than in the lymphocytic
nasal polyps (p = 0.03) (Table 6).
Table 6. CD25 immunoreactivity in nasal polyps.
The comparative analysis of MT and RCAS1 expression
and immune cell activity
A statistically significant correlation was found between
CD25 expression on immune cells and MT expression
in the epithelium of nasal polyps (r = 0.37, p = 0.02) as
Table 3 The immunoreactivity of CD68 in nasal polyps.
Variables Number CD68 immunoreactivity in nasal
polyps
-+ 1 + 2 + 3
Eosinophilic nasal polyps 21 0 0 1 (4.8%) 20 (95.2)
Lymphocytic nasal polyps 17 0 0 7 (41.2%) 10 (58.8%)
Table 4 The immunoreactivity of RCAS1 in nasal polyps
Variables Number RCAS1 immunoreactivity in
nasal polyps
-+ 1 + 2 + 3
Eosinophilic nasal polyps 21 0 19 (90%) 2 (10%) 0
Lymphocytic nasal
polyps
17 0 10
(58.8%)
4
(23.5%)
3
(17.7%)
Figure 4 RCAS1 positive macrophages within eosinophilic
nasal polyps (arrows).
Figure 5 RCAS1 positive macrophages migrating through the
epithelium of nasal polyps to the mucus (arrows).
Table 5 The immunoreactivity of CD4 in nasal polyps.
Variables Number CD4 immunoreactivity in nasal
polyps
-+ 1 + 2 + 3
Eosinophilic nasal polyps 21 11 (52%) 0 8 (38%) 2 (10%)
Lymphocytic nasal polyps 17 5 (29) 0 7 (42%) 5 (29)
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MT expression in the stroma of the nasal polyps
(r = 0.35, p = 0.03). No statistically significant correla-
tions were found, however, between MT and RCAS1
immunoreactivity on these same cells and tissues.
Discussion
In the present study, statistically significant differences
in MT expression in both the epithelium and stroma of
the nasal polyps with accompanying alterations in acti-
vation markers on immune cells and in the number of
macrophages were found when comparing the eosino-
philic and lymphocytic nasal polyps. In our previous
study, we demonstrated that nasal polyp tissue develops
a resistance to immune-mediated apoptosis in accor-
dance with increasing immune cell infiltration. This has
been recognized by evaluating the expression of DFF-45
and depended on the predominant immune cell infiltra-
tion profile. Nasal polyp tissue has also been shown to
regulate the activity of infiltrating immune cells by the
expression of RCAS1, a protein that inhibits the activity
of immune cells and induces their apoptosis [8]. To our
knowledge, this is the first investigation concerning MT
immunoreactivity in nasal polyps with regard to the
type of immune cell infiltration.
Nasal polyps are infiltrated by a variety of immunolo-
gical cells—eosinophils, neutrophils, plasma cells, mast
cells, and macrophages, lymphocytes, and their sub-
groups have all been found in nasal polyps [22]. The
lymphocytes that infiltrate nasal polyps have been iden-
tified as predominantly memory T cells in an activated
state and these produced a mixed Th1/Th2 cytokine
pattern (IFN-gamma and IL-5) [23]. In our study, no
differences were observed between the lymphocytic and
eosinophilic nasal polyps as far as CD4 antigen expres-
sion. The flow cytometry analysis of lymphocytes iso-
lated from nasal polyps revealed a significant increase of
IL-2 receptor and ICAM-1 molecule expression on
T cells isolated from nasal polyps when compared with
peripheral blood lymphocytes [24]. In our study, CD25
expression was present in both the eosinophilic and
lymphocytic nasal polyps and the level of expression
was statistically significantly higher in the eosinophilic
nasal polyps than in the lymphocytic polyps. This may
be a result of the intensity of the immune response in
these polyps and may suggest a greater number of cells
able to respond to the increased IL-2 expression. Higher
CD25 immunoreactivity in the eosinophilic nasal polyp
stroma in comparison to that in lymphocytic nasal
polyp stroma may also suggest the presence of Treg
cells typified by CD25 expression and may result from
the level of immune tolerance developing in the polyp
microenvironment due to chronic inflammation. Addi-
tionally, in the present study, a statistically significant
correlation was found between CD25 and MT immu-
noreactivity in the stroma of the nasal polyps (r = 0.35,
p = 0.03). While on the one hand this correlation may
result from MT immunoregulatory function [16], on the
other hand it could be the result of the development of
the resistance to immune-mediated apoptosis in the
stromal cells that are exposed to excessive immune
response in the microenvironment of the nasal polyps
and so may constitute a protective reaction by these
cells [16,25].
The accumulation of mannose-receptor positive
macrophages that has been reported in nasal polyps in
cell aggregates suggests that these cells play a key role
in the pathogen-macrophage interaction in nasal polyps
[7]. The number of macrophages in our study was sta-
tistically significantly higher in the eosinophilic than in
the lymphocytic nasal polyps. RCAS1-positive macro-
phages were identified only in the eosinophilic nasal
polyps. This may be due to the different type of immune
infiltration pattern in these kinds of nasal polyps.
RCAS1-positive macrophages are exclusively identified
in normal and pathological conditions; moreover, they
have been identified immunohistochemically among
macrophages in hematopoietic tissue [19]. Additionally,
RCAS1-positive macrophages have been found in the
peripheral blood of patients with Hodgkin’s lymphoma,
those with inflammatory liver diseases, and those suffer-
ing from ovarian endometriosis [21,20,26,27]. Because
RCAS1 is responsible for the regulation of immune cell
activity and may induce immune cell apoptosis, it is
possible that it participates in the immune suppression
phenomenon [28,29]. RCAS1-positive macrophages may
indeed suppress the activity of the infiltrating immune
cells. This mechanism may in turn help to develop
immune tolerance so that the nasal polyps maintain
their growth and development. Matushima et al.
observed RCAS1 only on activated macrophages in bone
marrow [19]; Enjoji et al., however, observed RCAS1-
expressing macrophages in the livers of patients with
inflammatory liver diseases [21]. Furthermore, the num-
ber of macrophages increased as the inflammation
increased [21]. In general, two types of macrophages can
be identified according to their respective functions: one
type promoting an antitumor immune response and the
Table 6 The immunoreactivity of CD25 in nasal polyps
Variables Number CD25 immunoreactivity in nasal
polyps
-+ 1+ 2 + 3
Eosinophilic nasal
polyps
21 2
(9.5%)
0 5 (23.8%) 14
(66.7%)
Lymphocytic nasal
polyps
17 0 0 10
(58.8%)
7 (41.2%)
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microenvironment. The M1 phenotypes interleukin 12
high, interleukin 23 high, and interleukin 10 low, along
with the production of reactive oxygen and nitrogen
intermediates and inflammatory cytokines, induce effec-
tor cells in Th1 responses. By contrast, the M2 pheno-
types, interleukin 12 low, interleukin 23 low, and
interleukin 10 high, participate in polarized Th2
responses. M2 tumor-associated macrophages were
shown to promote tumor proliferation and progression,
stimulate angiogenesis, and inhibit adaptive immunity
[30]. Since RCAS1-positive macrophages seem to exhibit
a regulatory function, we speculate that they belong to
the M2 phenotype, and we have recently described their
presence in the head and neck cancer microenvironment
[31].
The presence of RCAS1-positive macrophages in eosi-
nophilic nasal polyps may only prove that lymphocytic
nasal polyps differ from eosinophilic polyps with respect
to the degree of the disturbance in immune response
regulation that can be detected in the nasal polyp
microenvironment. The ongoing inflammation in the
nasal polyps may lead to a change in the function of the
macrophages related possibly to RCAS1 expression and
leading to the creation of the immune suppressive
microenvironment, thus helping to sustain local inflam-
mation. This may affect both the course of the disease
and the outcome of the treatment. Furthermore, such
polyps tend to recur.
The local inflammation enhances the infiltration of
immune cells and the accumulation of inflammatory
mediators that may injure the adjacent epithelium, thus
inducing the apoptosis of healthy cells. Normal cells
acquire resistance to immune-mediated apoptosis in
order to protect themselves against the inflammatory
process. The increasing resistance to immune-mediated
apoptosis was identified in our previous report by the
presence of decreased DFF-45 protein expression in
nasal polyp tissue [8] and most likely reinforces the
development of nasal polyps. MT was established as an
anti-apoptotic protein [32]. Intracellular MT expression
in nasal polyps may assure that a resistance to immune-
mediated apoptosis in nasal polyps is acquired. On the
one hand, MT seems to play a protective role against
apoptosis chiefly by maintaining the proper level of
intracellular zinc ions. This is because the level of these
intercellular ions is directly responsible for caspase-3
activity, which is in turn responsible for the DNA clea-
vage [33]. On the other hand, MT may also play an
important immunomodulating role and some have pro-
posed that it is a negative regulator of immune response
[16]. The level of MT expression in our study depended
on the pattern of immune infiltration and was found in
both the stroma tissue and bone fragments adjacent to
the nasal polyps, indicating the reaction of the entire
adjacent tissue to the increasing aggressiveness of the
immune response.
It has been demonstrated that the spread of the
inflammation in chronic rhinosinusitis may be related to
the inflammation taking place within the bony walls
underneath the inflamed mucosa of chronic rhinosinusi-
tis. The histopathological examination of ethmoid bone
fragments obtained from patients with chronic rhinosi-
nusitis revealed the presence of bone remodeling along
with the features of neo-osteogenesis [34]. „Osteitis” is
defined as a superficial inflammation of the bones with-
out the bone marrow spaces (flat bones) and is a variant
of osteomyelitis [35]. Because chronic rhinosinusitis may
induce the inflammatory process in the bones of the
paranasal sinuses, the presence of MT immunoreactivity
in the bones adjacent to inflamed mucosa may also be a
manifestation of the spread of the inflammatory process.
Conclusions
MT expression seems to favor the survival of nasal
polyp epithelial cells in the adjacent area of increasingly
cytotoxic immune activity. Additionally, the RCAS1-
positive macrophages present only in the eosinophilic
nasal polyps seem to be involved in creating the sup-
pressive microenvironment in nasal polyps.
Methods
Clinical material
Tissue samples were derived from the ENT Head and
Neck Surgery Department of the Jagiellonian University
during routine endonasal sinus surgery. The patient’s
consent was obtained in each case. Additionally,
approval for the research program was granted from the
Ethical Committee of the Jagiellonian University in Kra-
kow: KBET/90/B/2005. We recruited 100 patients from
those who had undergone functional endoscopic sinus
surgery between January 2005 and November 2006.
From this group of patients, 50 were selected for our
study. All the tissue samples were histopathologically
verified. Pathological analysis using the classical hema-
toxylin and eosin staining techniques after fixation in
formalin of the surgically removed material was per-
formed in the Pathology Department of the Jagiellonian
University by an experienced pathologist. The predomi-
nant immune cell infiltration in the nasal polyps was
determined under histopathological examination. Based
on this examination, three distinct types of polyps were
selected—eosinophilic nasal polyps, lymphocytic nasal
polyps, and neutrophilic nasal polyps. The criteria for
the selection of the different types of nasal polyps were
as follows:
Lymphocytic nasal polyps had a predominant infiltra-
tion of mononuclear cells; the percentage of eosinophilic
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membrane should not be thickened. Eosinophilic nasal
polyps had a predominantly eosinophilic cell infiltration
(not less than 90%), and the basal membrane was thick-
ened. Polyps that did not fulfill the above criteria, but
were infiltrated mainly by eosinophils with the percen-
tage of these cells exceeding 50%, were classified as eosi-
nophilic. Lastly, neutrophilic nasal polyps were
infiltrated mainly by neutrophils.
The tissue samples were divided into three main
groups according to the predominant immune cell infil-
tration: nasal polyps predominantly infiltrated by eosino-
phils or eosinophilic nasal polyps (21 cases); nasal
polyps predominantly infiltrated by lymphocytes or lym-
phocytic nasal polyps (17 cases), and nasal polyps predo-
minantly infiltrated by neutrophils or neutrophilic nasal
polyps (12 cases).
The clinical characteristics of the subjects are pre-
sented in Table 7.
In the group of patients classified as suffering from
lymphocytic nasal polyps, no concomitant diseases were
found though some individual patients did have asthma
and there were patients with single documented aller-
gies. The patients with eosinophilic nasal polyps differed
significantly from those with lymphocytic nasal polyps.
Immunohistochemistry
Immunohistochemical analysis was performed in the
Pathology Department of the Jagiellonian University. Five-
micrometer slides from each case were stained to visualize
the expression of RCAS1, MT, and CD4-, CD25-, and
CD68-positive cells. In all cases, immunohistochemistry
was performed applying the Envision method using Dako
Autostainer. The following antibodies were applied:
mouse monoclonal antibody Anti- RCAS1 (Medical and
Biological Laboratories, Naka-ku Nagoya, Japan in DAKO
Antibody Diluent with Background Reducing Compo-
nents-DAKO, Denmark, dilution 1:1000), monoclonal
mouse antibody ImmunOTM (MP Biomedicals, Inc.,
clone 1A12 in dilution 1:1000), CD68 (DAKO, clone
PG-M1 in dilution 1:50), CD4 (Novocastra, clone IF6 in
dilution: 1:50), CD25 (Interleukin-2 Receptor, NCL-CD25-
305, Novocastra in dilution 1:25), according to the manu-
facturer’s instructions. Visualization of reaction products
was performed using AEC (3-amino-9-ethyl-carbazole) as
a chromogen (AEC Substrate Chromogen ready-to-use,
DAKO, Denmark) for 10 minutes at room temperature.
Sections were counterstained with hematoxylin and
mounted in glycergel. As a positive control, a tonsil speci-
men was taken for RCAS1, while for metallothionein a
breast cancer specimen was obtained. All the stainings
were performed with the same procedure but with the
omission of the primary antibody as a negative control.
RCAS1 expression was evaluated in entire slides in the
area of nasal polyps, the epithelium, and the stroma
according to the following scale: 0 - no reactivity; +1 -
weak, when observed any (also granular in the paranuclear
region) cytoplasmic staining pattern (in up to 10% of posi-
tive cells); +2 - marked cytoplasmic (sometimes together
with membranous) staining in 11-30% of the cells; +3 -
high expression (more than 30% of positive cells). The
degree of metallothionein positivity was quantified as the
percentage of MT-positive cells in the nasal polyp slides.
The staining in the epithelial and stromal cells of the nasal
polyps was evaluated according to the following scale: 0 -
lack of any positivity; 1+ - weak staining in less than 5% of
the cells; 2+ - moderate - various staining intensity but in
<50% of the cells, 3+ - strong - staining of more than 50%
of the cells. The immune cells were calculated in an entire
specimen, in the region of nasal polyps and an average cell
number per 1hpf (high power field, objective magnification
×40) was calculated. Variable scales were used to evaluate
an amount of cells semi-quantitatively, depending on their
general number in the specimen. CD25+, CD4+, and
CD68+ cells were estimated according to the following
scale: 0 - lack of positive cells; +1 - single positive cells in
the specimen; +2 - 1-5 positive cells per 1hpf; +3 - more
than 5 positive cells/1hpf.
Statistical analysis
The distribution of variables in the examined groups of
patients checked with the use of the Shapiro-Wilk test
showed that all of them were different from normal.
Non-parametric testing was therefore employed. The sta-
tistically significant difference between the groups was
determined by the Kruskal-Wallis analysis of variance
Table 7 The clinical characteristics of the patient group.
Clinicopathological
findings
Nasal polyps (n = 50)
Lymphocytic
(n = 17)
Neutrophilic
(n = 12)
Eosinophilic
(n = 21)
Mean age 47
(± 14.96)
51
(± 16.9)
45.9
(± 15.67)
Male 64.7 (11) 50 (6) 52.4 (11)
Female 35.3 (6) 50 (6) 47.6 (10)
Microbial bacterial
infections
Staphylococcus aureus
Streptococcus
Enterococcus
Echerichia coli
- 41.6 (5) 23 (3)
Microbial fungal infections
Aspergillus
- - 19 (4)
Asthma 12 (2) - 38 (8)
NSAID intolerance - - 42 (9)
Documented allergy 23 (4) - 61 (13)
Nasal septum deviation 12 (2) - 10 (2)
All figures refer to the percentage of samples; n is the number of patients
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as appropriate. The data in the Tables is presented as
means ± standard error of the mean (SEM). A p value of
< 0.05 was accepted as statistically significant. The Spear-
man Rank Test was used to evaluate interclass correlation
coefficients. All calculations were carried out with the use
of STATISTICA software v. 6 (StatSoft, USA, 2001).
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